Bausch Health’s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary
Bausch Health Companies Inc. (NYSE: BHC ) is one of the 15 best NYSE penny stocks to buy according to hedge funds . On July 6, Bausch Health Companies Inc.'s (NYSE:BHC) subsidiary, Bausch Health Cana
Bausch Health Companies Inc. (NYSE: BHC ) is one of the 15 best NYSE penny stocks to buy according to hedge funds . On July 6, Bausch Health Companie
Read Full Story at Yahoo Finance →Why This Matters
The inclusion of PrOKEDI dosages in Quebec’s RAMQ formulary signals a critical step toward expanding access to novel therapeutic options for patients with severe dermatological conditions. For Bausch Health, this approval not only reinforces its positioning in Canada’s competitive pharmaceutical market but also serves as a strategic lever to drive revenue growth in a region where healthcare spending is increasingly scrutinized for innovation and cost-effectiveness.
Background Context
Bausch Health’s Canadian subsidiary has long operated in the shadow of its U.S. operations, which have faced regulatory and investor scrutiny over debt levels and patent cliffs. Quebec’s RAMQ formulary, meanwhile, is one of the most stringent in North America, often setting precedents for other provinces in drug pricing and reimbursement policies. The move comes amid broader industry shifts toward specialty dermatology drugs, where Bausch has been quietly building a portfolio to differentiate itself from larger rivals.
What Happens Next
With PrOKEDI now listed, Bausch will likely prioritize commercialization efforts to capture market share before competitors introduce similar treatments. Analysts will watch closely for pricing concessions or rebate negotiations with RAMQ, which could impact the drug’s profitability. Additionally, this approval may prompt other provinces to reconsider their own reimbursement policies, potentially expanding PrOKEDI’s reach across Canada.
Bigger Picture
This development reflects a growing trend of pharmaceutical companies targeting niche, high-margin therapies to offset revenue losses from patent expirations. It also highlights the strategic importance of Canada as a testing ground for drug pricing and access, where provincial formularies can drive global adoption. For Bausch, success here could validate its turnaround strategy and redefine its role in the dermatology drug landscape.
